Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Comparaison de deux approches comportementales pour arrêter de fumer dans des contextes de santé mentale (MTQT)

4 novembre 2026 mis à jour par: Wake Forest University Health Sciences

The study team will conduct a Multisite Randomized Controlled Trial to evaluate the advantages and disadvantages of two approaches for quitting smoking among people with serious mental illness (SMI). The study will compare a novel app tailored to people with SMI, Quit on the Go, to a standard of care smoking cessation intervention. We will test the effectiveness of the Quit on the Go app, an intervention that has demonstrated feasibility and acceptability in the target population, as a tool for smoking cessation in people with SMI. Participants with SMI will be recruited across 3 sites (Duke University, Univ. at Buffalo, and Wake Forest University).

Aperçu de l'étude

Description détaillée

Smoking tobacco shortens the lifespan of adults with serious mental illness by 25 years and contributes to 317 billion dollar expenditures in healthcare, indirect loss of earnings and disability benefits. Determining whether it is possible to deliver more effective and wider reaching smoking cessation interventions to individuals with serious mental illness is a high priority. Smartphone apps are a wide-reaching technology that could provide individuals with serious mental illness the necessary skills for quitting. However, our research has shown that apps developed for the general public have inadequate levels usability and engagement in people with serious mental illness.

In a previous pilot trial of a tailored smoking cessation app for people with serious mental illness, Learn to Quit (NCT03069482), we identified successful recruitment and retention methods for smokers with SMI, demonstrated a 4-fold increase in objectively measured interactions of the novel app, obtained promising cessation rates for the experimental app (12% for Quit on the Go formerly "Learn to Quit" versus 3% for NCI QuitGuide), and identified a reliable methodological approach to conduct a fully-powered randomized controlled trial.

Based on this pilot work, we plan to conduct a clinical trial to test this new model in a diverse and representative sample of the SMI population. Specifically, the proposed trial will test whether a tailored smoking cessation app for people with serious mental illness, Quit on the Go, results in higher levels of smoking abstinence compared to a standard of care intervention for this psychiatric population, Brief Advice. Both interventions will receive combined nicotine replacement therapy. The second aim of this trial is to test a mechanistic model of app efficacy by examining mediators of app engagement and treatment outcomes. Finally, the trial will evaluate the cost-effectiveness of these interventions to inform public health policy regard the use of mHealth in this population.

In a multi-site, two-arm randomized controlled trial, 450 individuals with serious mental illness will be randomly assigned to one of two conditions. In the experimental condition, participants will use the Quit on the Go app. In the comparator condition, participants will receive Brief Advice for smoking cessation. Participants in both conditions will receive combined Nicotine Replacement Therapy (standard dosing of nicotine patch plus 5 week course of nicotine gums). Study duration will be 6 months, with 3 follow-up appointments at 1-month, 3-month, and 6-months. Our proposed methods are appropriate given our established procedures during our pilot trial regard to participant assignment, delivery of interventions, data collection and analysis (NCT03069482).

The proposed study meets NIDA's major programmatic priorities of using innovative technologies (e.g., smartphones) and integrating behavioral and pharmacological interventions to improve substance use treatment and outcomes (NOT-DA-10-019). The proposal addresses a serious problem -- high smoking rates in people with SMI -- in a high priority, high cost population, by delivering a novel behavioral intervention for smoking cessation in "real-world" settings. If shown to be effective, the proposed intervention will provide a new model for delivering inexpensive, widely accessible smoking cessation interventions in adults with SMI.

Type d'étude

Interventionnel

Inscription (Réel)

343

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • New York
      • Buffalo, New York, États-Unis, 14260-1660
        • University at Buffalo
    • North Carolina
      • Durham, North Carolina, États-Unis, 27705
        • Duke University
      • Winston-Salem, North Carolina, États-Unis, 27157
        • Wake Forest Health Sciences

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. DSM-5 diagnosis of schizophrenia, schizoaffective, bipolar, recurring major depressive disorder or Persistent Depressive Disorder
  2. Functional impairment as indicated by a score of 2 or greater on the WHODAS 8 item version
  3. Smoker as indicated by smoking greater than or equal to 5 cigarettes per day over the past 6 months;
  4. Desire to quit smoking as indicated by self-reported serious intention to quitting tobacco within the next 6 months;
  5. Age 18 and older;
  6. Willing and medically eligible to use NRT;
  7. Currently receiving psychiatric treatment and intent to receive treatment for the duration of the study (therapy, medications, etc.).

Exclusion Criteria

  1. Problematic substance use, as defined by the Addiction Severity Index, within the last 30 days, twice within the past 6 months, or hospitalization for substance abuse within the past year.
  2. Current acute psychotic episode or unsafe to participate in the study as defined by the Mini International Neuropsychiatric Interview for Psychotic Disorders (Sheehan et al., 1998);
  3. Being pregnant or the intention to become pregnant in the next 6 months;
  4. Currently receiving any pharmacological and/or behavioral intervention or counseling for smoking cessation;
  5. Currently using e-cigarettes or other tobacco products besides cigarettes > 10 days in the past 30 days.
  6. Unsafe to participate in the study due to moderate or high risk of suicide determined by the Columbia-Suicide Severity Rating Scale (C-SSRS) - Screen Version, defined as answering 'yes' to both question 3 for the last month and 'yes' to question 6 for lifetime (moderate risk), or 'yes' to questions 4 and 5 for the recent month, or 'yes' to question 6 for the last 3 months (high risk).

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: "Quit on the Go" (formerly "Learn to Quit")

A smartphone app developed by the research team designed for people with serious mental illness, that provides Acceptance and Commitment Therapy skills to address (a) smoking cessation and (b) mental health symptoms. This app intervention is combined with an 8-week course of nicotine replacement therapy (NRT) patches and a 5-10 week course of NRT gum (or Nicotine Lozenges if unable to use gum). Participants also receive technical smartphone coaching for the first 4 weeks of the study.

A smartphone app developed by the research team designed for people with serious mental illness, that provides Acceptance and Commitment Therapy skills to address (a) smoking cessation and (b) mental health symptoms.

All participants will receive an 8-week course of transdermal nicotine patches. The first 4 weeks of use will be 21mg/24 hours, followed by 2 weeks of 14mg/24 hours patches, and finally 2 weeks of 7mg/24 hours patches.

Autres noms:
  • TRN

Participants randomized to the smartphone app intervention will receive 4 weeks of smartphone coaching given by research staff. The coaching is meant to be a time to address any issues that may rise with the participants' study smartphone or app.

Each participant enrolled will be given NRT gum (5-10week course) to be taken orally as nicotine cravings arise. Depending on participants' nicotine dependence, they will receive either the 2mg or 4mg (if they smoke within the first 30 minutes of waking) gum pieces per package instructions. We will direct subjects to use them for the first weeks following their quit date, using no more than one every 1-2 hours.

Autres noms:
  • TRN

In cases where participants are unable to chew nicotine gum, lozenges will be sent as a replacement of Nicotine gum. Depending on participants' nicotine dependence, they will receive either the 2mg or 4mg (if they smoke within the first 30 minutes of waking) lozenge pieces per package instructions. We will direct subjects to use them for the first weeks following their quit date, using no more than one every 1-2 hours.

Autres noms:
  • TRN
Autre: Brief Advice (Standard of Care)

Brief Advice and Combined Nicotine Replacement Therapy (patches and gum or lozenges) has been recommended by the US Clinical Practice Guidelines for patients with psychiatric illness. Brief Advice will consist of 20 minutes of guidance about the use of nicotine replacement therapy, and strategies to initiate and maintain a quit attempt. The intervention is combined with an 8-week course of nicotine replacement therapy (NRT) patches and a 5-10 week course of NRT gum (or Nicotine Lozenges if unable to use gum).

All participants will receive an 8-week course of transdermal nicotine patches. The first 4 weeks of use will be 21mg/24 hours, followed by 2 weeks of 14mg/24 hours patches, and finally 2 weeks of 7mg/24 hours patches.

Autres noms:
  • TRN

Each participant enrolled will be given NRT gum (5-10week course) to be taken orally as nicotine cravings arise. Depending on participants' nicotine dependence, they will receive either the 2mg or 4mg (if they smoke within the first 30 minutes of waking) gum pieces per package instructions. We will direct subjects to use them for the first weeks following their quit date, using no more than one every 1-2 hours.

Autres noms:
  • TRN

In cases where participants are unable to chew nicotine gum, lozenges will be sent as a replacement of Nicotine gum. Depending on participants' nicotine dependence, they will receive either the 2mg or 4mg (if they smoke within the first 30 minutes of waking) lozenge pieces per package instructions. We will direct subjects to use them for the first weeks following their quit date, using no more than one every 1-2 hours.

Autres noms:
  • TRN

Brief Advice will consist of 20 minutes of guidance about the use of nicotine replacement therapy, and strategies to initiate and maintain a quit attempt.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Bio-verified 7-day point-prevalence abstinence at 24 weeks
Délai: At 24 weeks from Baseline

Abstinence is binary, and requires both (a) self-report of no smoking at all for at least 7 days prior to week 24; and (b) biochemical verification [either expired CO breath test reading of < 5 ppm using the Belfont Micro+® Smokerlyzer test, or of < 6 ppm if using the iCOquit® Smokerlyzer test, or a cotinine level of less than or equal to 30 ng/ml if using an Alere iScreen saliva test]. If the participant does not meet both criteria, they are not considered abstinent.

As per convention, participants are assumed to be smoking if they report smoking at the time-point, cannot be reached to provide data at the time-point, or fail to provide a breath and saliva sample at the time-point.

At 24 weeks from Baseline

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change in average number of cigarettes smoked per day
Délai: At 24 weeks from Baseline

Change in self-reported number of cigarettes smoked per day, averaged within groups.

At 24 weeks from Baseline
Average number of 24-hr quit attempts per group
Délai: At 24 weeks from Baseline

Average number of quit attempts self-reported per group between baseline and week 24. Quit attempts are defined by no smoking at all for 24 hours or more.

At 24 weeks from Baseline
7-day point prevalence abstinence rates
Délai: At 12 weeks from Baseline

Percent of subjects in each group self-reporting no smoking at all for greater or equal to 7 days prior to the timepoint.

At 12 weeks from Baseline
7-day point prevalence abstinence rates
Délai: At 24 weeks from Baseline

Percent of subjects in each group self-reporting no smoking at all for greater or equal to 7 days prior to the timepoint.

At 24 weeks from Baseline
30-day point prevalence abstinence rates
Délai: At 12 weeks from Baseline

Percent of subjects in each group self-reporting no smoking at all for greater or equal to 30 days prior to the timepoint.

At 12 weeks from Baseline
30-day point prevalence abstinence rates
Délai: At 24 weeks from Baseline

Percent of subjects in each group self-reporting no smoking at all for greater or equal to 30 days prior to the timepoint.

At 24 weeks from Baseline
Biochemically confirmed 7-day point prevalence abstinence rates
Délai: At 12 weeks from Baseline

Percent of subjects in each group self-reporting no smoking at all for greater or equal to 7 days prior to the time point. Abstinence requires both (a) self-report of no smoking at all for at least 7 days prior to week 24; and (b) biochemical verification [either expired CO breath test reading of < 5 ppm using the Belfont Micro+® Smokerlyzer test, or of < 6 ppm if using the iCOquit® Smokerlyzer test, or a cotinine level of less than or equal to 30 ng/ml if using an Alere iScreen saliva test]. If the participant does not meet both criteria, they are not considered abstinent.

At 12 weeks from Baseline

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Average frequency of app use
Délai: Weeks 0-24

Average frequency of app use over the 24-week study period. Measured by average number of app openings.

Weeks 0-24
Average duration of app use
Délai: Weeks 0-24

Average duration of app use over the 24-week study period.

Weeks 0-24
Average number of app modules completed
Délai: Weeks 0-24

Average number of app modules completed over the 24-week study period.

Weeks 0-24
Average app usability scores
Délai: At 4 weeks from baseline

Average self-reported scores of usability on the 10-item System Usability Scale. Scores range from 0-100 with higher scores indicating higher usability of the app.

At 4 weeks from baseline
Average user experience scores
Délai: At 4 weeks from baseline

Average self-reported scores of user experience using the User Experience Questionnaire - Short Version.

At 4 weeks from baseline
Average user experience scores
Délai: At 12 weeks from baseline

Average self-reported scores of user experience using the User Experience Questionnaire - Short Version.

At 12 weeks from baseline
Average user experience scores
Délai: At 24 weeks from baseline

Average self-reported scores of user experience using the User Experience Questionnaire - Short Version.

At 24 weeks from baseline
Average acceptance of physical smoking cravings
Délai: At 4 weeks from baseline

Average self-reported scores of acceptance of cravings on the physical sensations subscale of the Avoidance and Inflexibility Scale. Scores range from 4-20 with lower scores indicating more acceptance of smoking cravings.

At 4 weeks from baseline
Average acceptance of physical smoking cravings
Délai: At 12 weeks from baseline

Average self-reported scores of acceptance of cravings on the physical sensations subscale of the Avoidance and Inflexibility Scale. Scores range from 4-20 with lower scores indicating more acceptance of smoking cravings.

At 12 weeks from baseline
Average acceptance of physical smoking cravings
Délai: At 24 weeks from baseline

Average self-reported scores of acceptance of cravings on the physical sensations subscale of the Avoidance and Inflexibility Scale. Scores range from 4-20 with lower scores indicating more acceptance of smoking cravings.

At 24 weeks from baseline
Nicotine patch use
Délai: At 12 weeks from baseline

Average number of days (out of 56 possible) per arm that participants used the nicotine patch.

At 12 weeks from baseline
Nicotine gum use
Délai: At 12 weeks from baseline

Average number of nicotine gum used per arm.

At 12 weeks from baseline
Smoking Costs at 4 Weeks
Délai: At 4 weeks from baseline

Average costs of smoking per group as measured by the Smoking Costs Questionnaire

At 4 weeks from baseline
Smoking Costs at 12 Weeks
Délai: At 12 weeks from baseline

Average costs of smoking per group as measured by the Smoking Costs Questionnaire

At 12 weeks from baseline
Smoking Costs at 24 Weeks
Délai: At 24 weeks from baseline

Average costs of smoking per group as measured by the Smoking Costs Questionnaire

At 24 weeks from baseline
Costs of technical coaching
Délai: At 24 weeks from baseline

Cost of technical coaching calls estimated by number of technical coaching calls to assist with the use of the QoG DTx

At 24 weeks from baseline
Experiences of racism at week 4
Délai: At 4 weeks from baseline

Self-reported experiences of racism per group as measured by the Everyday Discrimination Scale

At 4 weeks from baseline
Experiences of racism at week 12
Délai: At 12 weeks from baseline

Self-reported experiences of racism per group as measured by the Everyday Discrimination Scale

At 12 weeks from baseline
Experiences of racism at week 24
Délai: At 24 weeks from baseline

Self-reported experiences of racism per group as measured by the Everyday Discrimination Scale

At 24 weeks from baseline
Quality of Life at week 4
Délai: At 4 weeks from baseline

Self-reported quality of life per group as measured by the World Health Organization Quality of Life Scale - BREF

At 4 weeks from baseline
Quality of Life at week 12
Délai: At 12 weeks from baseline

Self-reported quality of life per group as measured by the World Health Organization Quality of Life Scale - BREF

At 12 weeks from baseline
Quality of Life at week 24
Délai: At 24 weeks from baseline

Self-reported quality of life per group as measured by the World Health Organization Quality of Life Scale - BREF

At 24 weeks from baseline
Frequency of e-cigarette use at Week 4
Délai: At 4 weeks from baseline

Average number of days of e-cigarette use per group as measured by a Timeline Follow Back Interview

At 4 weeks from baseline
Frequency of e-cigarette use at Week 12
Délai: At 12 weeks from baseline

Average number of days of e-cigarette use per group as measured by a Timeline Follow Back Interview

At 12 weeks from baseline
Frequency of e-cigarette use at Week 24
Délai: At 24 weeks from baseline

Average number of days of e-cigarette use per group as measured by a Timeline Follow Back Interview

At 24 weeks from baseline
Frequency of use of other tobacco products at week 4
Délai: At 4 weeks from baseline

Average number of days of use of other tobacco products per group as measured by a Timeline Follow Back Interview.

At 4 weeks from baseline
Frequency of use of other tobacco products at week 12
Délai: At 12 weeks from baseline

Average number of days of use of other tobacco products per group as measured by a Timeline Follow Back Interview.

At 12 weeks from baseline
Frequency of use of other tobacco products at week 24
Délai: At 24 weeks from baseline

Average number of days of use of other tobacco products per group as measured by a Timeline Follow Back Interview.

At 24 weeks from baseline
Frequency of use of cannabis at week 4
Délai: At 4 weeks from baseline

Average number of days of cannabis per group as measured by a Timeline Follow Back Interview.

At 4 weeks from baseline
Frequency of use of cannabis at week 12
Délai: At 12 weeks from baseline

Average number of days of cannabis per group as measured by a Timeline Follow Back Interview.

At 12 weeks from baseline
Frequency of use of cannabis at week 24
Délai: At 24 weeks from baseline

Average number of days of cannabis per group as measured by a Timeline Follow Back Interview.

At 24 weeks from baseline
Frequency of use of alcohol at week 4
Délai: At 4 weeks from baseline

Average number of days of alcohol use per group as measured by a Timeline Follow Back Interview.

At 4 weeks from baseline
Frequency of use of alcohol at week 12
Délai: At 12 weeks from baseline

Average number of days of alcohol use per group as measured by a Timeline Follow Back Interview.

At 12 weeks from baseline
Frequency of use of alcohol at week 24
Délai: At 24 weeks from baseline

Average number of days of alcohol use per group as measured by a Timeline Follow Back Interview.

At 24 weeks from baseline

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Roger Vilardaga, PhD, Wake Forest University

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

21 septembre 2021

Achèvement primaire (Réel)

30 décembre 2025

Achèvement de l'étude (Réel)

30 décembre 2025

Dates d'inscription aux études

Première soumission

26 août 2021

Première soumission répondant aux critères de contrôle qualité

26 août 2021

Première publication (Réel)

1 septembre 2021

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

9 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

4 novembre 2026

Dernière vérification

1 juillet 2025

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Oui

produit fabriqué et exporté des États-Unis.

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner